Last reviewed · How we verify
NCT05154851
HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.
trial testing HB-adMSCs in Congenital Muscular Dystrophy Due to Lamin A/C Mutation. No longer available.
Quick facts
| Lead sponsor | Hope Biosciences Research Foundation |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- HB-adMSCs — full drug profile →
Conditions studied
- Congenital Muscular Dystrophy Due to Lamin A/C Mutation — all drugs for Congenital Muscular Dystrophy Due to Lamin A/C Mutation →
Sponsor
Hope Biosciences Research Foundation
Who can join
Eligibility, any sex, with Congenital Muscular Dystrophy Due to Lamin A/C Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This individual patient expanded access IND is requested for a patient diagnosed with LMNA-related congenital muscular dystrophy (L-CMD). In this expanded access, the patient will receive the investigational product through 14 intravenous infusions, followed by Follow-Up visit and an End of Study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05154851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HB-adMSCs
Trials testing the same drug.
- NCT05116540 — Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis · Phase 2 · completed
- NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) · Phase 2 · completed
- NCT04348435 — A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. · Phase 2 · completed
- NCT04349631 — A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 · Phase 2 · completed
- NCT04228666 — A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-a · Phase 1, PHASE2 · withdrawn
Other Hope Biosciences Research Foundation trials
Trials by the same sponsor.
- NCT05126563 — Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome · Phase 2 · completed
- NCT05116540 — Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis · Phase 2 · completed
- NCT04995081 — Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) · Phase 2 · completed
- NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) · Phase 2 · completed
- NCT04362189 — Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05154851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hope Biosciences Research Foundation
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05154851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing